WallStreetZenWallStreetZen

NASDAQ: SPRY
Ars Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their SPRY stock forecasts and price targets.

Forecast return on equity

Is SPRY forecast to generate an efficient return?

Company
70.92%
Industry
74.01%
Market
170.14%
SPRY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SPRY forecast to generate an efficient return on assets?

Company
24.73%
Industry
29.14%
SPRY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SPRY earnings per share forecast

What is SPRY's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$1.57
Avg 2 year Forecast
-$0.65
Avg 3 year Forecast
$0.26

SPRY revenue forecast

What is SPRY's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$157.2M+86.55%
Avg 2 year Forecast
$291.7M+246.12%
Avg 3 year Forecast
$436.7M+418.21%
SPRY's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SPRY revenue growth forecast

How is SPRY forecast to perform vs Biotechnology companies and vs the US market?

Company
72.79%
Industry
33.61%
Market
14.12%
SPRY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SPRY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SPRY vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SPRY$8.01N/AN/A
KZIA$14.00$21.50+53.57%Strong Buy
ANRO$22.85$35.17+53.90%Strong Buy
ALLO$2.33$8.54+266.48%Strong Buy
RLMD$7.49$12.40+65.55%Strong Buy
View Top Biotech Stocks

Ars Pharmaceuticals Stock Forecast FAQ

What is SPRY's earnings growth forecast for 2026-2028?

(NASDAQ: SPRY) Ars Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.17%.

Ars Pharmaceuticals's earnings in 2026 is -$171,298,000.On average, 9 Wall Street analysts forecast SPRY's earnings for 2026 to be -$156,164,875, with the lowest SPRY earnings forecast at -$187,810,926, and the highest SPRY earnings forecast at -$123,029,363. On average, 9 Wall Street analysts forecast SPRY's earnings for 2027 to be -$64,970,228, with the lowest SPRY earnings forecast at -$122,612,315, and the highest SPRY earnings forecast at -$22,937,678.

In 2028, SPRY is forecast to generate $25,489,619 in earnings, with the lowest earnings forecast at -$89,526,452 and the highest earnings forecast at $100,091,685.

If you're new to stock investing, here's how to buy Ars Pharmaceuticals stock.

What is SPRY's revenue growth forecast for 2026-2028?

(NASDAQ: SPRY) Ars Pharmaceuticals's forecast annual revenue growth rate of 72.79% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.12%.

Ars Pharmaceuticals's revenue in 2026 is $84,278,000.On average, 9 Wall Street analysts forecast SPRY's revenue for 2026 to be $15,611,522,607, with the lowest SPRY revenue forecast at $13,064,546,682, and the highest SPRY revenue forecast at $18,048,278,520. On average, 9 Wall Street analysts forecast SPRY's revenue for 2027 to be $28,965,024,452, with the lowest SPRY revenue forecast at $19,817,756,531, and the highest SPRY revenue forecast at $34,146,357,931.

In 2028, SPRY is forecast to generate $43,367,105,859 in revenue, with the lowest revenue forecast at $31,334,258,197 and the highest revenue forecast at $54,529,116,139.

What is SPRY's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: SPRY) forecast ROA is 24.73%, which is lower than the forecast US Biotechnology industry average of 29.14%.

What is SPRY's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: SPRY) Ars Pharmaceuticals's current Earnings Per Share (EPS) is -$1.74. On average, analysts forecast that SPRY's EPS will be -$1.57 for 2026, with the lowest EPS forecast at -$1.89, and the highest EPS forecast at -$1.24. On average, analysts forecast that SPRY's EPS will be -$0.65 for 2027, with the lowest EPS forecast at -$1.23, and the highest EPS forecast at -$0.23. In 2028, SPRY's EPS is forecast to hit $0.26 (min: -$0.90, max: $1.01).

What is SPRY's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: SPRY) forecast ROE is 70.92%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.